Tag Archives: T-cell leukemia

No account yet? Register

Whole-Genome Landscape of Adult T Cell Leukemia/Lymphoma

The authors performed whole-genome sequencing of 150 adult T cell leukemia/lymphoma (ATL) cases and revealed the overarching landscape of genetic alterations in ATL.

[Blood]

[zotpress userid=” items=’BBBBBBBB’ style=’apa’ cite=’yes’]

Abstract

No account yet? Register

SCAMP2/5 as Diagnostic and Prognostic Markers for Acute Myeloid Leukemia

The authors explored expression patterns and prognostic value of secretory carrier-associated membrane proteins (SCAMPs) and network analysis of SCAMPs-related signaling pathways in acute myeloid leukemia using Oncomine, GEPIA, cBioPortal, LinkedOmics, DAVID and Metascape databases.

[Scientific Reports]

[zotpress userid=’7992332′ items=’ECRI9D8N’ style=’apa’ cite=’yes’]

No account yet? Register

Chronological Genome and Single-Cell Transcriptome Integration Characterizes the Evolutionary Process of Adult T Cell Leukemia-Lymphoma

Scientists developed and utilized a capture-based sequencing panel, which covered host hotspot genes and the full-length genome of human T-cell leukemia virus type-1, to investigate the clonal architecture of adult T-cell leukemia-lymphoma.

[Nature Communications]

[zotpress userid=’6445218′ items=’APST7FPM’ style=’apa’ cite=’yes’]

No account yet? Register

Abstract Graphical Abstract

The Requirement for Pyruvate Dehydrogenase in Leukemogenesis Depends on Cell Lineage

Investigators compared glucose metabolism in hematopoiesis and leukemia. Thymus T cell progenitors were glucose avid and oxidized more glucose in the tricarboxylic acid cycle through pyruvate dehydrogenase as compared with other hematopoietic cells.

[Cell Metabolism]

[zotpress userid=’7992332′ items=’NFFQPUBA’ style=’apa’ cite=’yes’]

No account yet? Register

Mutant Idh2 Cooperates with a NUP98-HOXD13 Fusion to Induce Early Immature Thymocyte Precursor ALL

In vitro treatment of Idh2R140Q/NHD13 thymocytes with enasidenib, a selective inhibitor of mutant IDH2, led to a marked decrease in leukemic cell proliferation, demonstrating that Idh2R140Q/NHD13 mice could serve as a useful in vivo model for the study of early/immature T cell precursor acute lymphoid leukemia (ALL) development and therapy.

[Cancer Research]

[zotpress userid=’7992332′ items=’KAYBYJ2A’ style=’apa’ cite=’yes’]

Abstract

No account yet? Register

Single-Cell Chromatin Accessibility Landscape of Human Umbilical Cord Blood in Trisomy 18 Syndrome

Scientists used the commercial Chromium platform to perform sc-ATAC-seq to measure chromatin accessibility in 11,611 single umbilical cord blood cells derived from one trisomy 18 syndrome patient and one healthy donor.

[Human Genomics]

[zotpress userid=” items=’T2H3CY6P’ style=’apa’ cite=’yes’]

No account yet? Register

AAV-Mediated In Vivo CAR Gene Therapy for Targeting Human T-Cell Leukemia

Investigators described a novel approach in which human chimeric antigen receptor (CAR T) cells could be generated within the host upon injecting an adeno-associated virus (AAV) vector carrying the CAR gene, which they called AAV delivering CAR gene therapy.

[Blood Cancer Journal]

[zotpress userid=” items=’IA7G38N3′ style=’apa’ cite=’yes’]

No account yet? Register

industry & policy

HUYABIO International Receives Regulatory Approval for HBI-8000 Monotherapy of Adult T-Cell Leukemia/Lymphoma in Japan

HUYABIO International™ announced the regulatory approval for HBI-8000 monotherapy of relapsed or refractory adult T-cell leukemia/lymphoma (ATL) by the Japanese Pharmaceuticals and Medical Devices Agency. The drug was approved based on data from a Phase IIb study that involved 23 patients with aggressive ATL in Japan.

[HUYABIO International^TM (PR Newswire, Inc.)]

[zotpress userid=’7992332′ items=’nan’ style=’apa’ cite=’yes’]

Press Release

No account yet? Register

industry & policy

Shorla Pharma Announces FDA Filing Acceptance and Priority Review for T-Cell Leukemia Treatment

Shorla Pharma Limited announced that it has submitted, and the FDA has accepted for filing, its application for its SH-111 oncology drug designed to treat T-cell leukemia.

[Shorla Pharma Limited (BusinessWire, Inc.)]

[zotpress userid=’6445212′ items=’nan’ style=’apa’ cite=’yes’]

Press Release

No account yet? Register

Overexpression of Aberrant Wnt5a and Its Effect on Acquisition of Malignant Phenotypes in Adult T-Cell Leukemia/Lymphoma (ATL) Cells

Scientists demonstrated that the overexpression of c-Myb and FoxM1 was responsible for the synergistic activation of the WNT5A promoter.

[Scientific Reports]

[zotpress userid=’6445212′ items=’LPBNWFS3′ style=’apa’ cite=’yes’]